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Structural microdomains of G protein-coupled recep-
tors (GPCRs) consist of spatially related side chains that
mediate discrete functions. The conserved helix 2/helix
7 microdomain was identified because the gonado-
tropin-releasing hormone (GnRH) receptor appears to
have interchanged the Asp2.50 and Asn7.49 residues
which are conserved in transmembrane helices 2 and 7
of rhodopsin-like GPCRs. We now demonstrate that dif-
ferent side chains of this microdomain contribute spe-
cifically to receptor expression, heterotrimeric G pro-
tein-, and small G protein-mediated signaling. An Asn
residue is required in position 2.50(87) for expression of
the GnRH receptor at the cell surface, most likely
through an interaction with the conserved Asn1.50(53)
residue, which we also find is required for receptor ex-
pression. Most GPCRs require an Asp side chain at ei-
ther the helix 2 or helix 7 locus of the microdomain for
coupling to heterotrimeric G proteins, but the GnRH
receptor has transferred the requirement for an acidic
residue from helix 2 to 7. However, the presence of Asp
at the helix 7 locus precludes small G protein-dependent
coupling to phospholipase D. These results implicate
specific components of the helix 2/helix 7 microdomain
in receptor expression and in determining the ability of
the receptor to adopt distinct activated conformations
that are optimal for interaction with heterotrimeric and
small G proteins.
The gonadotropin-releasing hormone (GnRH)1 receptor be-
longs to the rhodopsin-like family of G protein-coupled recep-
tors (GPCR) (1). This family includes the light-sensitive opsins,
protease-activated receptors, and receptors for neurotransmit-
ters, peptides, and glycoproteins. High resolution structural
data have not yet been obtained for any GPCR. However,
projection maps of rhodopsin, amino acid sequence alignment,
and computational modeling indicate that GPCRs have 7 mem-
brane-spanning a-helices (2–6). There is a high degree of ho-
mology within the transmembrane helices and certain amino
acids are highly conserved throughout the family (2, 3, 7). This
diverse family shares the common function of propagating a
signal across lipid membranes and the amino acid side chains
which are conserved among the GPCRs are likely to constitute
key structural motifs which subserve this universal GPCR
function.
Several models of GPCRs, including the GnRH receptor (4,
8), have been constructed as aids for investigating receptor
structure-function relations. Molecular models of GPCRs can
be used to integrate experimental observations and generate
structural hypotheses. However, the complexity of these struc-
tures and the limited number of experimentally determined
constraints can lead to inconsistent behavior of the models (4,
7). To overcome these limitations, we have pursued the ap-
proach of identifying discrete structural motifs within receptor
models, which might constitute functional microdomains. The
microdomains are characterized in detail and subsequently
incorporated into whole receptor models. In the GnRH recep-
tor, for example, this approach has recently been used to pro-
pose that the motion of the conserved Arg3.50(139) side chain is
restricted by interaction with the conserved Asp3.49(138) and the
presence of a b-branched, hydrophobic residue, Ile3.54(143) (see
“Experimental Procedures” for a description of the amino acid
numbering scheme). Incorporation of this microdomain into the
whole receptor model suggests that receptor activation is ac-
companied by repositioning of the Arg3.50(139) side chain, allow-
ing it to interact with the Asp7.49(318) side chain in transmem-
brane helix 7 (H7) in the activated receptor conformation (4).
A related GPCR structural motif consists of this H7 side
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chain (usually Asn7.49) and the conserved 2.50 residue (usually
Asp) in H2. The H2/H7 microdomain was originally identified
from the apparent interchange of these side chains in the
GnRH receptor and its functional importance was supported by
reciprocal mutagenesis studies (8). Reciprocal mutation exper-
iments in the serotonin 5-HT2A (9), thyrotropin releasing hor-
mone (TRH) (10), m opioid (11), and NK2 tachykinin receptors
(12) have all shown that the disruption of signal transduction
observed with mutation of the Asp2.50 side chain in H2 is
restored by a second mutation in H7 that interchanges the two
conserved residues.
While the inter-related roles of these H2 and H7 side chains
in receptor activation (9–12) suggest that they constitute a
structural and functional microdomain, this conclusion has
been considered controversial (13, 14). The initial study of this
microdomain in the GnRH receptor reported that the presence
of an Asp residue in both loci eliminated detectable binding.
This result raised the possibility that charge repulsion was
responsible for the observed phenotype. However, the presence
of Asp at both positions in wild-type non-mammalian GnRH
receptors (15, 16) and in several other GPCRs (3) as well as in
functional mutant GPCRs (9, 10, 14, 17) indicates that the side
chains in this microdomain, that are compatible with function,
differ among GPCRs.
For a specific receptor, the side chains of the H2/H7 microdo-
main may contribute to receptor expression and receptor acti-
vation and coupling to intracellular signal transduction. The
molecular events that underlie receptor activation are a key
question in understanding receptor function. Studies of many
receptors have implicated the H2/H7 microdomain as a key
component of this process (9–11, 18). The involvement of this
domain in multiple distinct receptor functions may account for
the different results observed in the various receptors studied.
The side chain at the 7.49 locus has also recently been impli-
cated in specifying small G protein-dependent coupling to PLD
(19). In order to elucidate the role of this microdomain in the
GnRH receptor, we have investigated the functional require-
ments of each locus in receptor expression, coupling to hetero-
trimeric G protein-dependent signal transduction, and cou-
pling to the small G protein, ADP-ribosylation factor (ARF).
EXPERIMENTAL PROCEDURES
Amino Acid Residue Numbering—To allow comparison of equivalent
residues in different GPCRs, amino acids in the transmembrane seg-
ments of the GnRH receptor are numbered relative to the most con-
served residue of the rhodopsin-like GPCRs, as described previously (7).
Thus, Asn87, which is located in the position of the most conserved
residue in H2, is designated Asn2.50(87), while Asp318, which is adjacent
to the most conserved residue in H7 (Pro7.50(319)), is designated
Asp7.49(318).
DNA Constructs, Cell Culture, and Transfection—The mutations
N2.50(87)D, N2.50(87)Q, N2.50(87)A, D7.49(318)N, D7.49(318)E, and
D7.49(318)A were introduced into the mouse GnRH receptor as de-
scribed previously (8) using the Altered Sites Mutagenesis System
(Promega, Madison, WI), while the mutations N1.50(53)A, N1.50(53)D,
N1.50(53)L, and D7.49(318)L were generated using QuikChange (Strat-
agene, La Jolla, CA). Two epitope tags were applied to the GnRH
receptor to allow detection of the receptor by Western blotting. An
amino-terminal HA-tag (YPYDVPDYA) was inserted after the initial
Met residue of the wild-type GnRH receptor by polymerase chain reac-
tion. Since the mouse GnRH receptor does not have a cytosolic carboxyl-
terminal domain, a carboxyl-terminal domain derived from a putative
human type II GnRH receptor (20) was appended to allow addition of a
carboxyl-terminal hexahistidine tag using a combination of polymerase
chain reaction and multifragment subcloning into the pcDNA3 expres-
sion vector (Invitrogen, San Diego, CA). The carboxyl-terminal seven
amino acids of the carboxyl-terminal domain were substituted with six
histidine residues to generate a hexahistidine tag. All DNA constructs
were sequenced to confirm the presence of mutations and epitope tags.
COS-1 cells were maintained in Dulbecco’s modified Eagle’s medium
containing 10% fetal bovine serum and transfected as described previ-
ously, using LipofectAMINE (Life Technologies Inc., Gaithersburg, MD)
(21). Cells to be used for intact cell functional assays were seeded into
12- or 24-well plates the day after transfection.
Ligand Binding Assays—[D-Ala6,Pro9-NHEt]GnRH (GnRH-A,
Bachem, Torrance, CA), was radioiodinated using IODO-GEN (Pierce
Chemical Co., Rockford, IL) following published protocols (22). Whole
cell binding assays were performed as described (23). Briefly, trans-
fected cells, in 24-well plates, were incubated for at least 2 h at 4 °C
with 125I-GnRH-A (60,000 cpm/well) and varying concentrations of un-
labeled GnRH-A or GnRH (Bachem, Torrance, CA) in a total volume of
0.4 ml/well. The incubation was terminated by removal of the medium
and bound radioactivity was collected in 1 M NaOH. Nonspecific binding
was determined in the presence of 1027 M unlabeled GnRH-A.
Membrane binding assays were performed as described previously
(24) on some low-expressing constructs because this method makes it
possible to increase receptor concentration in the assay by varying the
amount of membrane added to incubation tubes. Cell membranes were
resuspended in protein-free binding buffer (1 mM EDTA, 10 mM
HEPES, pH 7.5) and incubated for 90 min on ice with 125I-GnRH-A
(200,000 cpm), 0.1% bovine serum albumin and varying concentrations
of GnRH-A. The reaction was terminated by filtration through GF/C
filters (Brandel Inc., Gaithersberg, MD) which were presoaked in bind-
ing buffer containing 1% bovine serum albumin, and washed twice with
binding buffer.
Immunoblotting—Transfected cells (9-cm dishes) were washed with
phosphate-buffered saline prior to harvesting and homogenization in
lysis buffer (50 mM Tris, pH 7.5, 1 mM phenylmethylsulfonyl fluoride, 1
mM EDTA, and 10 mg/ml leupeptin). The homogenate was centrifuged
for 10 min at 500 3 g and 4 °C and the resulting supernatant was
centrifuged at 35,000 3 g for 20 min at 4 °C. The membrane pellet was
resuspended in lysis buffer (30 ml/3 3 106 transfected cells) and solu-
bilized by gentle shaking for 15 min on ice in the presence of CHAPS at
a final concentration of 15 mM. The solubilization mixture was centri-
fuged for 30 min at 35,000 3 g and 4 °C to remove particulate material,
and the resulting supernatant was incubated with N-glycosidase F
(Roche Molecular Biochemicals, Indianapolis, IN, 0.2 units per 20 ml of
supernatant) for 30 min at 37 °C. Samples were electrophoresed under
reducing conditions on NuPAGE polyacrylamide gels (Novex, San Di-
ego, CA) according to the manufacturer’s instructions and electro-
blotted onto nitrocellulose membranes (Hybond C Pure, Amersham
Pharmacia Biotech) in the presence of 0.04% SDS. Blots were blocked
for at least 1 h in blot buffer (5% non-fat dry milk, 20 mM Tris, pH 7.5,
150 mM NaCl) before incubation overnight in Tetra-His antibody (Qia-
gen, Valencia, CA, 0.2 mg/ml in blot buffer). Bound antibody was de-
tected using the ECL Western blotting kit (Amersham Pharmacia
Biotech).
Phosphatidylinositol Hydrolysis—Accumulation of inositol phos-
phates (IP) in the presence of Li1 was determined according to pub-
lished protocols (25). Transfected cells were labeled for 16 h in Dulbec-
co’s modified Eagle’s medium containing 0.5 mCi/ml myo-[3H]inositol
(NEN Life Science Products, North Billerica, MA). After washing with
serum-free medium the cells were incubated for 45 min at 37 °C with
varying concentrations of GnRH in the presence of 20 mM LiCl. The
incubation was terminated by removal of the medium and addition of 10
mM formic acid. [3H]IP was separated from the formic acid extracts on
Dowex-1 ion-exchange columns and eluted with 1 M ammonium formate
and 0.1 M formic acid.
PLD Assay—Activation of PLD was determined by a transphosphati-
dylation assay as described previously (26). Transfected cells in 12-well
plates were labeled overnight with [3H]palmitate in serum-free mini-
mum essential medium. After washing with minimal essential medium
containing HEPES (25 mM, pH 7.5) and 1% fatty acid-free bovine serum
albumin, cells were preincubated for 30 min at 37 °C with various
concentrations of brefeldin A (BFA) in HEPES-buffered minimal essen-
tial medium with 0.5% bovine serum albumin, before addition of butan-
1-ol (30 mM) and GnRH (1 mM) and incubation for a further 30 min.
Reactions were terminated by removal of the medium and addition of
0.5 ml of cold methanol to each well. Phospholipids were extracted and
separated on Whatman LK5D thin layer chromatography plates as
described (26).
Data Analysis—Kd and Bmax values for binding of GnRH-A were
determined using the LIGAND computer program (27). Protein levels
were determined by the Lowry method. IC50 (concentration required for
50% inhibition of 125I-GnRH-A binding) values for GnRH were esti-
mated using nonlinear curve fitting (KaleidaGraph, Synergy Software,
Reading, PA). EC50 (agonist concentration required for half-maximal
response) values for IP production were calculated using KaleidaGraph.
IP data were fitted to the equation E 5 Emax/(1 1 EC50/D), where the


























Emax is the maximum IP accumulation and D is the concentration of the
agonist. Transient transfection of the wild-type GnRH receptor into
COS-1 cells leads to expression of an appreciable level of “spare recep-
tors” which results in an EC50 for IP accumulation that is significantly
lower than the Kd for GnRH binding to the receptor (21). Because of the
receptor reserve in the wild-type receptor and the varied expression
levels of the mutant receptors, simple comparison of maximal IP accu-
mulation does not yield an accurate measure of how well a particular
receptor is activated. To facilitate comparison of mutant receptor acti-
vation, we have utilized a previously derived expression of receptor
coupling efficiency, Q, which is defined as: Q 5 0.5 3 [(Kd 1 EC50)/EC50]
3 (Emax/Bmax) (4). IC50 values for GnRH were used as an approximation
of Kd.
RESULTS
H2 Mutants Are Not Expressed, but Expression Is Restored in
H2/H7 Reciprocal Mutant—The effects of amino acid substi-
tutions at each locus of the H2/H7 microdomain were studied.
The substitutions introduced for Asn2.50(87) (Gln, Asp, and Ala)
were designed to test the effects of altered size, charge, and
polarity on receptor function. None of the single H2 mutant
constructs studied exhibited detectable ligand binding activity,
IP accumulation, or ARF-dependent accumulation of phos-
phatidyl butanol (PtdBut) (Table I).
To determine whether the lack of ligand binding by the H2
mutants resulted from altered receptor expression, we utilized
an immunoblot assay of epitope-tagged receptor constructs.
The parent epitope-tagged construct had an amino-terminal
HA-tag and a carboxyl-terminal domain with a hexahistidine
tag (see “Experimental Procedures”). The effects of epitope
tagging on receptor function were evaluated. All H2 and H7
mutant constructs were epitope-tagged and tested in ligand
binding and IP accumulation assays. The tagged wild-type and
mutant receptors mediated IP accumulation with EC50 values
which were comparable to those of corresponding untagged
receptors. For all constructs with measurable ligand binding,
Kd values were unchanged and Bmax values elevated with
epitope tagging. As was observed for the untagged receptors,
ligand binding was not detectable in the epitope-tagged
N2.50(87)D and N2.50(87)A constructs (Table II). The epitope-
tagged N2.50(87)Q construct exhibited low, but measurable
ligand binding (Table II). This tagged construct also mediated
a low level of GnRH-stimulated IP accumulation (not shown).
The relative receptor expression, as measured by ligand bind-
ing, and the function of the tagged receptors closely paralleled
that of the untagged receptors, thus validating the use of the
tagged receptors in protein expression assays.
Western blots of the epitope-tagged wild-type receptor
yielded a broad band of 55–85 kDa (not shown) which was
compressed to a single band at 34 kDa after deglycosylation
(Fig. 1). This pattern resembles that reported for the photoaf-
finity-labeled GnRH receptor (28). To increase sensitivity of
detection and facilitate comparison of band intensity, all recep-
tors were deglycosylated prior to immunoblot analysis. At a
level of sensitivity which yielded an intense band for the
epitope-tagged wild-type receptor, only a faint signal was vis-
ible for the H2 mutants in which Asn2.50(87) was substituted
with Asp, Gln, or Ala (Fig. 1). Thus, the low or absent binding
TABLE II
Ligand binding of epitope-tagged GnRH receptors with mutations in
H2
Membranes prepared from COS-1 cells transfected with wild-type
and epitope-tagged wild-type and mutant GnRH receptors were incu-
bated with 125I-GnRH-A (200,000 cpm) and increasing concentrations of
unlabeled GnRH-A. Membrane protein concentrations ranged from 48
to 62 mg/ml for wild-type receptors, while 400–900 mg/ml was used for
cells transfected with H2 mutant receptors and vector to enhance the
sensitivity of receptor detection. The low binding of the mutant recep-
tors prevents reliable calculation of Bmax values, thus maximum specific
binding is reported to indicate relative expression levels.
Construct Maximum specific binding IC50, GnRH-A
fmol/mg protein nM
Wild type 86.5 6 10.9 0.91 6 0.05
Tagged wild type 226.3 6 27.3 1.06 6 0.09
Tagged N2.50(87)D 1.78 6 0.08
Tagged N2.50(87)Q 9.3 6 2.2 1.23 6 0.03
Tagged N2.50(87)A 0.05 6 0.25
pcDNA3 0.38 6 0.44
TABLE I
Summary of ligand binding, immunoblot, IP accumulation, and PtdBut accumulation assays in mutant GnRH receptors
Ligand binding parameters were determined from competition binding assays using 125I-GnRH-A as tracer. Data are mean 6 S.E. from three
to five experiments performed in triplicate. Immunoblotting was performed on epitope-tagged receptor constructs as described under “Experi-
mental Procedures.” The carboxyl-terminal hexahistidine tag was detected with the tetra-His antibody and the relative intensity of the bands is
indicated by the number of 1 signs. IP accumulation was determined in transfected COS-1 cells labeled with myo-[3H]inositol. Data are mean 6
S.E. from three to five experiments performed in triplicate. The efficiency of receptor coupling to activation of PLC was calculated from the
summarized data in this table using the formula described under “Experimental Procedures” and expressed as a percentage of the wild-type
receptor coupling efficiency. ARF-dependent PLD activity was determined as the accumulation of PtdBut in the presence of GnRH (1026 M) with
and without BFA (0.2 mM) and expressed relative to the PtdBut accumulation in the absence of GnRH and BFA.
Construct











% wt nM % wt -fold basal
Wild-type 582 6 135 1.2 6 0.6 20 6 15 1111 100 0.85 6 0.46 100 21.6 6 1.5
N2.50(87)D Unda 12 21.5 6 0.7 0.4 6 0.5
N2.50(87)Q Und 12 2.2 6 0.7 20.4 6 0.4
N2.50(87)A Und 12 0.1 6 0.5 0.1 6 0.4
N2.50(87)D/
D7.49(318)N
170 6 46 1.3 6 0.77 32 6 20 111 11.7 6 4.5 30 6 18 3.3 3.2 6 0.6
D7.49(318)N 386 6 42 0.97 6 0.23 27 6 18 111 38.9 6 11.7 45 6 29 3.8 4.7 6 0.6
D7.49(318)E 30 6 3 2.3 6 1.4 33 6 7 11 36.6 6 6.5 20 6 10 76.7 0.3 6 1.0
D7.49(318)A 610 6 156 0.71 6 0.22 22 6 14 111 12.0 6 0.1 42 6 18 0.7 0.1 6 0.7
D7.49(318)L Und 11 3.6 6 0.2
N1.50(53)D Und 12 4.3 6 3.3
N1.50(53)A Und 12 4.3 6 4.1




a Constructs in which total binding was too low to estimate Bmax are reported as undetectable.
b n 5 1.


























and coupling of these constructs is associated with very low
levels of receptor protein.
In contrast to the results obtained with single H2 mutants,
the reciprocal mutant, N2.50(87)D/D7.49(318)N, exhibited li-
gand binding (Table I), as described previously (8). In addition,
this receptor was also clearly visible on immunoblot analysis,
yielding a band which had lower intensity than that of the
wild-type receptor (Fig. 1).
Differing Expression of H7 Mutants—The functions of GnRH
receptors with Asp7.49(318) mutated to Asn, Glu, and Ala were
studied to evaluate the role of size, hydrogen bonding, and ionic
interactions at this locus. All of these H7 mutants bound
GnRH-A with affinities similar to that of the wild-type receptor
(Fig. 2, Table I). The maximal binding of these constructs
varied, with Asp (wild-type) $ Ala . Asn . Glu (Table I, Fig.
2). Immunoblot detection of the epitope-tagged H7 mutants
correlated with the expression levels measured by ligand bind-
ing (Fig. 1). The high expression of the Ala7.49(318) and
Asn7.49(318) mutants shows that the negative charge and hydro-
gen bonding functions of the Asp side chain are not critical for
efficient receptor expression. In contrast, the D7.49(318)E mu-
tant, which conserves the carboxylate functional group, had
greatly reduced expression, both by binding (5.2% of wild-type,
Table I) and by immunoblot (Fig. 1). These results indicate that
the H7 interaction imposes specific steric constraints that are
optimal for Asp and are only poorly matched by a negatively
charged side chain of a larger size. To test whether the low
expression of the Glu7.49(318) mutant was due to poor tolerance
of the larger bulk of the Glu side chain, or to misalignment of
the carboxyl group, Asp7.49(318) was substituted with Leu. The
low expression of the D7.49(318)L mutant relative to the
D7.49(318)A construct (Table I, Figs. 1 and 2) suggests that the
reduced expression of the D7.49(318)E receptor results from
the increase in bulk of the side chain and not from altered
positioning of the carboxyl group.
H1 Mutants Are Not Expressed, and the H1/H7 Reciprocal
Mutant Does Not Restore Expression—The high expression of
the non-polar H7 mutant, Ala7.49(318), shows that the low ex-
pression of the H2 mutants is not due to loss of an interaction
with the H7 side chain. It has been proposed, for other GPCRs,
that the 2.50 side chain interacts with the highly conserved
Asn1.50 side chain in H1 (10, 18). To test whether the low
expression of the H2 mutants might be due to disruption of an
interaction with Asn1.50(53) in the GnRH receptor, this residue
was mutated to Asp, Ala, and Leu. All H1 mutant constructs
exhibited no measurable ligand binding or GnRH-stimulated
accumulation of IP (Table I) and yielded only faintly detectable
bands on immunoblots (Fig. 1). A reciprocal mutant,
N1.50(53)D/D7.49(318)N, was constructed to test whether the
locus 7.49 side chain influences the function of the Asn1.50(53)
side chain. This reciprocal mutant showed no recovery of the
ligand binding and IP accumulation which is lost in the H1,
N1.50(53)D single mutant (Table I).
Phospholipase C (PLC) Activation—While all of the H7 mu-
tants (except for Leu7.49(318)) were capable of mediating GnRH-
stimulated IP production, the EC50 values were increased and
Emax values decreased in comparison with the wild-type GnRH
receptor (Fig. 3A, Table I). The magnitude of IP stimulation
observed did not correlate with levels of mutant receptor ex-
pression. For example, the D7.49(318)A construct, which ex-
pressed at wild-type levels, exhibited low maximal IP response
(12% of wild-type Emax). In contrast, the poorly expressed
D7.49(318)E mutant showed a relatively high IP signal (36.6%
of wild-type Emax). These results reveal distinct side chain
requirements for expression and for coupling to PLC.
An empirical measure of receptor coupling efficiency that
estimates the functional response achieved per agonist-occu-
pied receptor was calculated for each construct, as described
previously (4) (see “Experimental Procedures”). The rank order
of coupling efficiency for PLC was: wild-type, Asp . Glu .
Asn . reciprocal H2D/H7N . Ala (Fig. 3B, Table I). It was not
possible to calculate coupling efficiency for the D7.49(318)L
mutant because of its lack of measurable binding and IP accu-
mulation. The low efficiency of the Ala and Asn mutants indi-
cates the importance of the polar and ionic functions of the
native Asp side chain in PLC coupling. However, the high
efficiency of the D7.49(318)E construct shows that a carboxy-
late side chain is required for efficient coupling to PLC.
It is notable that the PLC coupling efficiency of the reciprocal
mutant (with Asp in H2, Asn in H7) was lower than for the
D7.49(318)N single mutant (Table I, Fig. 3B). In other PLC-
coupled GPCRs, mutants containing Asn residues at both the
2.50 and 7.49 loci were poorly coupled (9, 10), a result which we
also see in the GnRH receptor (Table I). However, in contrast to
the other GPCRs studied, where reciprocal mutation restored
coupling (9, 10), the GnRH receptor appears unique in that the
poor coupling persists with the interchange mutations. These
commonalties and differences have implications for under-
standing the pattern of intramolecular signal transduction as-
sociated with GnRH receptor activation (see “Discussion”).
They may also represent the special properties or importance of
an Asp side chain in H7 in the GnRH receptor (18), which is
present in the wild-type receptor in species from bony fish to
mammals.
PLD Activation—We have recently reported that the BFA-
sensitive component of PLD activation depends on receptor
interaction with small G proteins in the ARF/RhoA family (19).
FIG. 1. Immunoblot of GnRH receptor constructs. COS-1 cells
were transfected with epitope-tagged wild-type and mutant GnRH re-
ceptor constructs as described under “Experimental Procedures.” Cell
membranes were solubilized, deglycosylated, electrophoresed, and
transferred to nitrocellulose membrane as described. Epitope-tagged
receptors were detected with an antibody generated against
tetrahistidine.
FIG. 2. 125I-GnRH-A competition binding. COS-1 cells were trans-
fected with wild-type GnRH receptor (●) or mutant constructs
D7.49(318)N (E), D7.49(318)E (M), D7.49(318)A (f), D7.49(318)L (),
and N2.50(87)D/D7.49(318)N (ƒ) and incubated with 125I-GnRH-A and
increasing concentrations of unlabeled GnRH-A as described under
“Experimental Procedures.” Data are the mean 6 S.E. of a represent-
ative experiment performed in triplicate.


























GnRH was found to stimulate PtdBut accumulation via the
wild-type receptor and all of the H7 mutants (Fig. 4, Table I).
However, only the response mediated by the D7.49(318)N mu-
tant and the N2.50(87)D/D7.49(318)N reciprocal mutant exhib-
ited the BFA sensitivity characteristic of coupling to the small
G protein, ARF (Fig. 4, Table I). Thus, in contrast to heterotri-
meric G-protein coupling, coupling to ARF appears to have a
stringent requirement for an Asn residue at position 7.49. This
requirement may relate to stabilization of different activated
receptor conformations when the side chain at this position is
varied (see “Discussion”).
DISCUSSION
The H2/H7 microdomain of the GnRH receptor is unusual
among GPCRs in having an Asn residue at position 2.50(87).
Our study of the role of each side chain of the microdomain in
distinct GnRH receptor functions supports the importance of
this structural microdomain and reveals the elements of the
microdomain that are necessary for each function. The Asn in
H2 is required for stable receptor expression and the Asp in H7
is critical both for efficient coupling to PLC and for excluding
ARF-dependent coupling to PLD.
Requirement for Asn2.50(87) in Receptor Expression—All mu-
tations of the Asn residue in H2 profoundly disrupted receptor
expression. This resulted in a loss of signal in ligand binding
assays, second messenger determination, and immunoblot
analysis. The immunoblot results indicate that the loss of re-
ceptor-binding sites for the H2 mutants most likely results
from a decrease in membrane receptor protein. Mutations that
led to intracellular retention of receptor (29) and receptor pro-
tein instability (30) have been reported for the b-adrenergic
receptor. Thus, the loss of GnRH receptors with mutations of
H2 could be due either to disruption of biosynthesis and traf-
ficking to the membrane or to instability and degradation of the
expressed receptor.
The requirement for an Asn2.50(87) residue in H2 for expres-
sion is an unusual feature of the GnRH receptor. Furthermore,
the detrimental effect of the simultaneous presence of Asp at
both the 2.50 and 7.49 loci on receptor expression is not ob-
served in most other GPCRs studied (9, 10, 12, 17, 31). Incor-
poration of a second Asp residue in the H2/H7 microdomain, by
mutating the Asn7.49 residue to Asp in the 5-HT2A, TRH, cho-
lecystokinin B (CCKB), and NK2 receptors, which have Asp at
position 2.50, caused relatively modest decreases in receptor
Bmax levels (9, 10, 12, 14). Only the m-opioid receptor is similar
to the GnRH receptor in manifesting complete loss of binding
with Asp present at both the H2 and H7 loci (11). The ability of
some GPCRs to tolerate Asp side chains at both loci has led
some workers to conclude that the H2 and H7 side chains are
unlikely to be in close proximity (14). However, crystallo-
graphic studies reveal that Asp side chains can occur in close
proximity within proteins and can form hydrogen bonds when
one of the Asp side chains is protonated (32, 33). Thus, the
tolerance of Asp residues at both loci in various GPCRs does
not exclude proximity of the side chains of the H2/H7 microdo-
main. Differences in the complement of amino acids that con-
stitute the microenvironment of this domain in different recep-
tors most likely determine the specific side chains that are
tolerated at each position. The present results and data from
all other GPCRs studied are consonant with spatial proximity
of the conserved H2 and H7 side chains.
In view of the profound decrease in expression observed with
substitutions for Asn2.50(87), it is difficult to draw firm conclu-
sions from mutagenesis studies about the role of this side chain
in receptor coupling. The detection of some receptor function
with the epitope-tagged N2.50(87)Q mutant suggests that pre-
serving a polar amide side chain at this position may preserve
receptor function to a greater extent than the other substitu-
tions tested. While a role of Asn2.50(87) in receptor activation
cannot be inferred from the present data, such a role would be
consistent with previously reported computational studies
which suggest that both Asn2.50(87) and Asp7.49(318) interact
with the conserved Arg3.50(139) side chain to stabilize the active
state of the receptor (4).
H7 Side Chain at the 7.49 Locus Is Not Required for Receptor
Expression—We have demonstrated that restoration of GnRH
receptor binding with the reciprocal mutation, N2.50(87)D/
D7.49(318)N, is accompanied by restoration of receptor expres-
sion, as determined by immunoblotting. These results suggest
that the strict requirement for Asn in position 2.50 can be
satisfied by insertion of an amide side chain in the spatially
FIG. 3. Coupling to PLC. GnRH-stimulated accumulation of IP was
measured (top panel) in COS-1 cells transfected with wild-type (●) and
D7.49(318)N (E), D7.49(318)E (M), D7.49(318)A (f), and N2.50(87)D/
D7.49(318)N () mutant GnRH receptor constructs. Data are the
mean 6 S.E. of a representative experiment performed in triplicate.
PLC coupling efficiencies (lower panel) were calculated from the data in
Table I to facilitate comparison of receptor-mediated activation of PLC,
independently of effects on receptor expression.
FIG. 4. Coupling to PLD. GnRH-stimulated accumulation of [3H]
PtdBut was measured in COS-1 cells transfected with wild-type (●) and
D7.49(318)N (E), D7.49(318)E (M), and D7.49(318)A (f) mutant GnRH
receptor constructs. Transfected cells were stimulated with GnRH (1
mM) in the presence of increasing concentrations of the ARF inhibitor,
BFA. Data are the mean 6 S.E. of four to ten experiments performed in
duplicate.


























adjacent 7.49 locus. Alternatively, a charged Asp side chain can
substitute for the Asn2.50(87) side chain in the GnRH receptor
when a destabilizing interaction with the H7 side chain is
removed by substitution of the charged Asp7.49(318) residue with
an uncharged Asn residue. The relatively high expression of
the D7.49(318)A mutant indicates that a direct interaction
between the 2.50 and 7.49 side chains is not required for
receptor expression. This mutant was the best expressed of the
mutant receptors in this study, but since the side chain of Ala
is non-polar, it cannot form a hydrogen bond with the residue in
position 2.50. It has been proposed that the Asp2.50 side chain
of the TRH receptor forms hydrogen bonds with both the
Asn7.49 side chain and the highly conserved Asn1.50 side chain
in H1 (10). The Asn1.50(53) residue is conserved in the GnRH
receptor and, based on computational modeling (4, 8), could
interact with the Asn2.50(87) side chain. Our results showing
that an interaction with Asp7.49(318) is not required for expres-
sion of the GnRH receptor, suggested that an interaction be-
tween the side chains of Asn2.50(87) and Asn1.50(53) may be
required for stable receptor expression. Mutation of Asn1.50(53)
to Ala, Asp, or Leu also yielded constructs with very low ex-
pression, similar to the H2 mutants. The similar phenotypes of
mutants with subtle changes in H1 or H2 is consistent with,
and supports a role for a hydrophilic interaction between these
side chains in stabilizing expression of the GnRH receptor. A
reciprocal mutant, N1.50(53)D/D7.49(318)N, did not recover
the function lost in the H1 mutants, showing that the H7 side
chain does not influence the function of the H1 side chain in the
same way as it does the H2 side chain. This is consistent with
molecular models which show polar interactions of the 2.50
side chain with the 1.50 and 7.49 side chains, but no direct
interaction between the 1.50 and 7.49 loci (7, 10, 18, 34).
The high levels of expression observed with mutations of the
Asp7.49(318) to either Asn or Ala indicate that the functional
features of the Asp side chain are not required for efficient
receptor expression. In fact, the H7 mutant which preserves
the acidic group, D7.49(318)E, had much lower expression than
receptors with Ala or Asn substitutions at this position. These
data reveal that expression is sensitive to the length of the
negatively charged side chain at position 7.49. These results
suggest that a larger side chain at position 7.49 may interfere
with receptor assembly, either through steric interference that
would disrupt helix packing due to increased bulk of the side
chain, or through a disruption of protein folding by misalign-
ment of the carboxyl group. To determine whether the detri-
mental effect of the Glu7.49(318) mutation on receptor function
was due to the increased bulk of the side chain or to unfavor-
able positioning of the carboxyl group, Asp7.49(318) was mutated
to Leu. The low expression of this mutant indicates that the
receptor cannot accommodate a bulky side chain in this
position.
Acidic Side Chain Required at Locus 7.49 for Efficient Acti-
vation of PLC—In contrast to the poor expression seen with the
mutation of Asp7.49(318) to Glu, the PLC coupling efficiency of
this mutant is comparable to that of the wild-type receptor
(Table I, Fig. 3B). In contrast, the D7.49(318)A mutant was
well expressed and yet was nearly uncoupled from PLC activa-
tion (Table I, Fig. 3). The preservation of the PLC coupling
efficiency of the D7.49(318)E mutant, which conserves the neg-
ative charge of the Asp side chain, indicates that a carboxylate
side chain is necessary for efficient activation of heterotrimeric
G proteins. The rank order of the coupling efficiency of mutants
with H7 side chain substitutions, Asp . Glu . Asn . Ala, is
consistent with the involvement of ionic and hydrogen bonds in
the interactions of these side chains with the highly conserved
Arg3.50(139) residue. These data are consistent with our pro-
posal that an interaction between the Arg3.50(139) and
Asp7.49(318) side chains stabilizes receptor activation (4).
The amino acid side chains in the H2/H7 microdomain of the
GnRH receptor that are required for efficient coupling to het-
erotrimeric G proteins differ from those required in other
GPCRs. In GPCRs which have the canonical wild-type Asp-Asn
arrangement of the microdomain, the Asp2.50 side chain is
required for efficient G protein coupling (9, 10, 12, 14, 31). In
addition, a polar residue is required in H7. Mutation of Asn7.49
to Ala significantly uncoupled the b2-adrenergic, angiotensin
AT1, serotonin 5-HT2A, TRH, and NK2 tachykinin receptors (9,
10, 12, 17, 35). However, mutation of Asn7.49 to Asp had min-
imal effects on the coupling of the b2-adrenergic, serotonin
5-HT2A, TRH, CCKB, and NK2 receptors (9, 10, 12, 14, 17). The
ability of Asp, but not Ala, to substitute for the conserved
Asn7.49 residue suggests that hydrogen bonding interactions of
Asn7.49 may be required for efficient coupling of these recep-
tors. Thus, single site mutation experiments show that activa-
tion of these GPCRs requires an acidic (Asp) residue in position
2.50 and a polar residue (Asn or Asp) in the 7.49 locus. Recip-
rocal mutation of this microdomain in the 5-HT2A, TRH, m-opi-
oid, and NK2 receptors has shown that moving the Asp side
chain from H2 to H7 results in a significant recovery of the
uncoupling which results from the loss of the Asp side chain at
position 2.50 (9–12). Thus, for many GPCRs, the presence of an
Asp in the H2/H7 microdomain is required for efficient cou-
pling, but the Asp may be located at either position 2.50 or 7.49.
In the GnRH receptor, single mutations of Asp7.49(318) show
that this receptor also requires an acidic residue for coupling to
PLC (Table I, Fig. 3). However, unlike the other GPCRs, the
movement of the Asp side chain within the microdomain (from
H7 to H2 in the double mutant) does not preserve efficient PLC
coupling. Thus, in the GnRH receptor, the Asp residue which is
required for efficient coupling appears to have been transferred
from H2 to H7 in comparison with other GPCRs. Furthermore,
the GnRH receptor has fixed the requirement for the acidic side
chain at the H7 locus. The structural basis for these unique
features of the GnRH receptor may be determined by the var-
ious non-conserved side chains that contribute to the environ-
ment of the H2/H7 microdomain, including the special proper-
ties of the H7 structure which, in the GnRH receptor, has 2
NP/DP motifs (18).
The non-mammalian GnRH receptors have Asp residues in
both the H2 and H7 loci (15, 16). The presence of the two Asp
residues in these receptors raises the possibility that the non-
mammalian GnRH receptors represent evolutionary interme-
diates between the conserved Asp-Asn arrangement found in
most GPCRs and the Asn-Asp arrangement found in all mam-
malian GnRH receptors (1). Like the mammalian GnRH recep-
tor, the non-mammalian, catfish receptor exhibited decreased
coupling when the Asp residue in H7 was mutated to Asn (15).
As in the present study, lack of ligand binding activity pre-
vented analysis of H2 mutants of the catfish GnRH receptor
(15), so it is not possible to determine whether the carboxylate
function of the H2 Asp side chain is required for coupling of the
non-mammalian GnRH receptor. In contrast, the platelet acti-
vating factor receptor, which also has Asp residues at both loci,
retained coupling to PLC when the H7 Asp residue was mu-
tated, but was uncoupled when the H2 Asp residue was mu-
tated (36), showing that this receptor retains its Asp residue
coupling function in H2.
Asn7.49(318) Required for ARF-mediated Activation of PLD—
Computational simulations of agonist binding to the wild-type
and D2.50N mutant serotonin 5HT2A receptors showed that
agonist binding induces a conformational rearrangement of the
mutant receptor which is different from the agonist-induced


























conformation of the wild-type receptor (9). This suggests that
mutant GPCRs that do not have an Asp residue in the H2/H7
microdomain are able to assume an activated conformation, but
that this conformation is different from the activated confor-
mation of the wild-type receptors that have an Asp residue in
this microdomain. Mutation of the Asp2.50 side chain has vari-
able effects on signal transduction in different receptors (9, 31).
Mutating the Asp2.50 residue of the a2-adrenergic receptor had
differential effects on different signal transduction pathways.
The D2.50N mutant a2-adrenergic receptor retained the ability
to mediate inhibition of adenylyl cyclase and calcium currents,
but could not achieve the conformation necessary for activation
of the distinct G proteins that mediate activation of potassium
channels (37).
The GnRH receptor mutants which lack an acidic residue in
the H2/H7 microdomain were poorly coupled to activation of
PLC. In contrast, the D7.49(318)N mutant and the N2.50(87)D/
D7.49(318)N reciprocal mutant gained the capacity to mediate
ARF-dependent activation of PLD (Table I, Fig. 4). Further-
more, as previously demonstrated, the reciprocal mutant
(N2.50(87)D/D7.49(318)N) also shows a pattern of PtdBut ac-
cumulation characteristic of ARF-dependent signaling (19).
Thus, mutant receptors which do not efficiently adopt the ac-
tivated conformation necessary for activation of heterotrimeric
G protein-dependent signaling were, nevertheless, able to ac-
tivate the small G protein, ARF. The requirement for an Asn
residue at position 7.49 for ARF-mediated coupling to PLD is
shared by all GPCRs in which BFA-sensitive coupling has been
studied (19). For example, a mutant of the serotonin 5-HT2A
receptor with Asp substituted for Asn7.49 retained coupling to
PLC, but lost BFA-sensitive coupling to PLD (19). This shows
that the presence of a carboxylate side chain in the 7.49 locus
prevents interaction of agonist-occupied GPCRs with the
ARFzRhoA complex, regardless of the ability to activate hetero-
trimeric G proteins. Computational studies of the 5-HT2A re-
ceptor indicate that the activated receptor conformation of the
wild-type (Asn7.49) receptor differs from that of the ARF-uncou-
pled N7.49D mutant in the conformation of the activated form
of the receptor, but not of the inactive form.2 These results
suggest that the optimal receptor conformation which mediates
heterotrimeric G protein-dependent PLC coupling differs from
the conformation required for ARF-mediated PLD coupling and
that the capacity to assume a conformation for coupling to ARF
requires an Asn side chain at position 7.49.
We find that different side chain elements of the H2/H7
microdomain in the GnRH receptor are required for specific
receptor functions. The GnRH receptor is unusual among
GPCRs in requiring Asn residues both at position 2.50 and
position 1.50 for receptor expression, and in its transfer of the
acidic residue required for efficient PLC activation from locus
2.50 to 7.49. The presence of an Asp side chain in position
7.49 in the wild-type GnRH receptor serves to prevent ARF-
dependent coupling to PLD, in common with other receptors
which have an Asp residue in this position (19). These find-
ings indicate that the H2/H7 microdomain forms a critical
part of the machinery that underlies activation of the rho-
dopsin-like GPCRs, and that it exhibits specific structure-
related properties that are revealed by comparison of the
GnRH receptor with other GPCRs.
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